Brazilian Pharmaceutical Market Outlook 2016-2026

LONDON, September 6, 2016 /PRNewswire/ --

Revenue Forecasting of Originator, Generic and OTC Medicines and Therapy Areas Including CNS, Cardiovascular and Cancer; Exploration of Regional Differences in Healthcare; Discussion of Domestic Manufacturers Including EMS, Hypermarcas and Aché, and International Drug Companies Including Sanofi, Novartis and Roche

Medicine Sales in Brazil - How to Find Trends, Opportunities and Forecasted Revenues
Do you want to assess Brazil's pharmaceutical market from 2016? If so, visiongain's new report gives you revenue forecasts, helping your research and analysis. That study's purpose is to show opportunities, trends and sales predictions to 2026.

Brazil can satisfy expectations for wider healthcare coverage and rapid expansion of its pharma industry and market. With our updated study you explore business analysis, developments and opportunities for domestic and foreign companies.

Please read on to explore Brazilian medical sales and see how high that fast developing country's revenues could go.

Trends and outlooks for that emerging healthcare market - what is possible?
From 2016 patients, treatment providers and the pharmaceutical industry will benefit from progress in Brazilian healthcare. Discover in our study what the future holds - medical needs and potential revenues. Also find rankings of companies.

Our new analysis shows you revenue predictions from 2016 to 2026 at overall national and submarket levels. You discover the most lucrative parts of that country's drug market, seeing opportunities to benefit patients, healthcare providers and pharma companies. Explore what the future holds for domestic producers and multinational pharma companies.

Forecasts and other data help you find where the money lies in Brazil's medical sales
To support our forecasting, our work shows you historical results, sales growth rates and market shares. In our 191 page report you gain 52 tables, 55 charts and interviews with representatives from BiocadBrazil Farmaceutica and Sandoz Brazil.

With our study, see how you could save time and avoid struggles to find data to help your research, analysis, plans and presentations. See, too, how you could help your influence, benefiting your reputation for commercial insight on Brazilian pharma.

To see a report overview please email Sara Peerun on [email protected]

The following sections show how our investigation helps your work.

Potential of Brazil's drug sales - overall market and segment forecasts
What is Brazil's potential as a pharma market? In our analysis you discover overall revenues to 2026, with discussions. Our report also shows you individual sales predictions - from 2016 to 2026 - for three main submarkets:
• Patented therapies - original brands of prescription drugs
• Generic pharmaceuticals (generics)
• OTC medicines - over-the-counter treatments.

The future looks promising for Brazilian pharmaceutical sales. That developing national market is growing at a faster rate than more-mature markets, and can continue to do so over the next ten years. See what is possible.

With our study also extend your knowledge of that country's medical needs and pharma industry. In addition you explore forecasting for therapeutic applications, assessing demand and potential revenues.

Diseases and their treatment - what prospects for drugs and their sellers?
Our new study also predicts revenues in Brazil for treating prominent diseases. See individual revenue forecasts to 2026 for six therapeutic categories:
• Central nervous system (CNS)
• Cardiovascular (CV)
• Gastrointestinal and metabolic
• Cancer treatments (oncology)
• Infectious diseases - anti-infective agents (vaccines and antibiotics)
• Therapies for other disorders (grouped analysis).

How fast will those submarkets expand? How high will their revenues go? With our report you assess opportunities and potentials, seeing what developments and sales are possible.

There you also investigate what stimulates and restrains sales of drugs.

Issues and events in Brazil - what affects drug developers, producers and sellers?
Our study discusses forces affecting Brazil's medical sales from 2016, including these influences:
• Efforts of companies and public healthcare providers to serve patients' needs
• Strategies of domestic and foreign companies, including mergers and acquisitions (M&A), drug launches, sales ranking and Brazilian market share
• Trends in demographics, economics and epidemiology - assess medical needs, including Zika virus infection
• Wholesalers, distributors and retailers of medicines - the supply chain
• Governmental policies - explore activities of ANVISA and SUS and other bodies - including the new drug price adjustment system, the RENAME reimbursement programme and ANVISA reform of patent protection.

With our study you also assess these influences, among others:
• Efforts by regions to improve medical provision, better serving populations
• Healthcare insurance - public and private - to improve access to medicines
• Technologies - competitors' research and development and manufacturing
• Technology transfer and IP protection, including action against counterfeiting
• Rising demand for biological drugs, including biosimilars
• Brazil's position in overall world, Latin American, BRIC nations and pharmerging countries' pharmaceutical markets.

With our analysis you examine political, economic, social and technological questions, assessing commercial prospects. You also investigate strengths, weaknesses, opportunities and threats.

Explore what stimulates and restrains domestic and foreign pharmaceutical companies in Brazil, discovering what is possible from 2016 to 2026.

Analysis of top companies and their industry - what future sales are possible?
What happens next? Our work predicts the Brazilian pharma market will reach $31.1bn in 2020 - with strong expansion from 2016 to 2026. See what is possible.

In our report you discover what causes that sales growth and why Brazil attracts and develops pharma business. There you explore activities of 10 leading domestic companies and other firms, including these organisations:
• EMS
• Hypermarcas
• Aché
• Eurofarma
• Cristália
• Libbs
• União Química.

You also assess 10 multinational - big pharma - organisations and other foreign players operating there, including these corporations:
• Sanofi
• Novartis
• Roche
• Pfizer
• Takeda
• Bayer
• Merck & Co.

You also see interviews with BiocadBrazil Farmaceutica and Sandoz Brazil. Discover the efforts of pharma specialists, including firms making biopharmaceuticals. From 2016 many firms stand to gain.

Leading generic and biosimilar drug developers, producers and sellers
In our report you assess other international manufacturers and marketers of drugs for Brazil, including generics and biosimilars:
• Teva Pharmaceutical Industries
• Mylan
• Actavis
• Daiichi Sankyo
• Glenmark
• Valeant
• Strides Arcolab
• Biocon.

Pharma industry leaders and specialty companies will expand their operations and sales there. Explore what is possible in Brazil and see how you could benefit.

5 ways Brazilian Pharmaceutical Market Outlook 2016-2026 helps your work
In these five main ways, our investigation gives knowledge to benefit your research, analyses and decisions:
• Brazil's overall pharma revenues from 2016 - discover that leading developing country's prospects for medical investments, marketing and sales
• Submarkets' revenues to 2026 - investigate 9 segments at national level, finding product groups and therapeutic needs with highest potential revenues
• Prospects for domestic and foreign drug developers, producers and sellers - explore portfolios, R&D, product approvals, collaborations, M&A and outlooks
• Opinion and news from companies - see views to help you stay ahead in knowledge, including two interviews
• Analysis of what stimulates and restrains Brazil's market for human medicines - assess challenges and strengths there, helping you compete and gain advantages.

That study, by our in-house analysts in the UK, gives data to benefit your work. Our survey shows information you find nowhere else, helping you stay ahead.

Independent analysis showing you the potential of Brazil's pharma sales
Our report gives analysis showing you the most promising opportunities. Discover progress and possibilities for pharmaceutical sales in Brazil.

Through choosing our study, see how you could save time and effort, also benefiting your authority and reputation for commercial insight.

Our investigation is for everyone analysing rising and emerging pharma markets. Brazil holds great commercial potential - our study shows you trends, forecasts and discussions to help you stay ahead in knowledge. So avoid missing out - please get our new report here now.

To see a report overview please email Sara Peerun on [email protected]

To request a report overview of this report please emails Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1719/Brazilian-Pharmaceutical-Market-Outlook-2016-2026

Organisations Mentioned in the Report 

Abbott Laboratories

Aché Laboratórios Farmacêuticos S.A

Actavis PLC

Agência Nacional de Saúde Suplementar (ANS)

Agência Nacional de Vigilância Sanitária (ANVISA)

Agila Specialties Private Ltd

Allianz Saúde

Alteogen Inc

AMB (Brazilian Medical Association)

American Diabetes Association ADA)

AmerisourceBergen Corporation (ABC)

Amgen Inc

Antaris Consulting

Associação Brasileira das Redes de Farmácias e Drogarias (ABRAFARMA)

Associação Brasileira de Reabilitação de Coluna (Brazilian Association of Back Rehabilitation)

Associação da Industria Farmacêutica de Pesquisa (Interfarma)

Associação Nacional de Assistencia ao Diabetico (ANAD)

Astellas Pharma Inc

AstraZeneca PLC

Athos Farma SA

Axis Biotec Brasil

Baxter International Inc

Bayer AG

Bergamo Ltda

Beth Israel Hospital

Bill & Melinda Gates Foundation

Billi Farmacêutica

Biocad

BiocadBrazil Farmaceutica

Biocon Limited

Biolab Emcure Farmaceutica Comercial Ltda

Biolab Farmaceutica

Bio-Manguinhos (Instituta de Tecnologia em Imunobiologicos)

Biomm SA

Bionovis SA

Biovail Corporation

Boehringer Ingelheim GmbH

Boiron

Brainfarma Indústria Química e Farmacêutica

BrasilPharma

Brazil Produtos Roche Químicos e Farmacêuticos

Brazilian Institute of Tax Planning

Brazilian National Bank for Economic and Social Development (BNDES)

Brazilian National Institute of Social Security (INSS)

Bristol-Myers Squibb (BMS)

British Medical Journal (BMJ)

BTG Pactual

Bunker Industria Farmaceutica

Butantan Institute

Câmara de Regulação do Mercado de Medicamentos (CMED)

Care Plus Medicina Assistencial S/S Ltda

Ceitec SA

Celesio AG

Centre for Economics and Business Research (CEBR)

Chemo Group

Claris Lifesciences Ltd

Conselho Federal de Farmácia

Conselho Federal de Medicina (CFM)

Corporacion Infarmasa SA

Cosmed Industria de Cosmeticos e Medicamentos

Cristália

CVS Pharmacy

Daiichi Sankyo

Delta

Dimed SA

Distribuidora Farmacêutica Panarello Ltda

DM Industria Farmacêutica Ltda

Drogaria Sao Paulo

Drogarias DPSP SA

Drogarias Farmais

Drogarias Pacheco

Drogarias Tamoio

Drogasil SA

Eisai Co Ltd

Eli Lilly & Co

Emcure Pharmaceuticals Ltd

Empresas Andromaco

EMS

Eurofarma

Eurofarma Argentine

Eurofarma Chile

Eurofarma Uruguay

European Medicines Agency (EMA)

Everis Group

F. Hoffmann-La Roche AG

Farmácia Ben

Farmácia Popular

Farmacias Mais Econômica

Farmácias Guararapes

Farmalife

Farmanguinhos (Instituto de Tecnologia em Farmacos)

Farmindustria SA

Federação Nacional de Saúde Suplementar (FenaSaúde)

Federal Court of Rio de Janeiro

Food and Drug Administration (FDA)

Forest Laboratories Inc

Fundação Oswaldo Cruz (FioCruz)

Fundação Ezequiel Dias (Funed)

Genzyme Corporation

Germed Pharma

Gilead Sciences Inc

GlaxoSmithKline PLC (GSK)

Glenmark Pharmaceuticals

Golden Cross

Government of Brazil

Grünenthal Group

Grupo Amil Saúde

Grupo Bradesco Saúde

Grupo Cimed

Grupo Notre Dame Intermédica Saúde

Grupo SulAmérica Saúde

Hapvida Assistência Médica

Health Canada

Health Network Formation and Quality Improvement Project (QualiSUS)

Hebron

Hemobrás

Horizon Pharma PLC

Hospital das Clínicas, São Paulo

Hospital Israelita Albert Einstein

Hospital Santa Catarina

Hypermarcas

IMA Laboratories

Indar Institute

Indian Council of Medical Research

Innova Pharma

Institute for Health Insurance (IESS)

Instituto Brasileiro de Geografia e Estatística (IBGE)

Instituto de Estudos de Saúde Suplementar (IESS)

Instituto de Tecnologia do Paraná (TECPAR)

Instituto Terapeutico Delta

Instituto Vital Brazil

Janssen

Johnson & Johnson

Kantar Health

Kenya Medical Research Institute

Laboratório Daudt Oliveira

Laboratório Farmacȇutico do Estado de Pernambuco (LAFEPE)

Laboratório Prata

Laboratório Sanobiol

Laboratório Teuto

Laboratorio Volta

Laboratório Tiaraju

Laboratórios Gautier

Laboratórios Klinger Do Brasil

Laboratorios Laprin S.A

Lazard

Legrand Pharma Industria Farmaceutica Ltda

Libbs Biotec

Libbs Farmacêutica Ltda

Luper Indústria Farmacêutica

mAbxience

Mantecorp Quimica Industria e Farmaceutica Ltda

Médecins sans Frontières (MSF)

Medley Farmacêutica

Meizler Biopharma SA

Melcon Indústria Farmacêutica SA

Merck & Co., Inc

Merck KGaA

Merck Serono

Mercosur

Merial

Merz  Pharma GmbH & Co. KGaA

Metlife Exclusivamente Odontológicos

Metropolitan Life Insurance Company

Minas Gerais State Department of Health

Ministry of Health of Malaysia

Ministry of Health, Brazil

Moksha8

Multilab Industria e Comerci de Produtos Farma

Mundipharma International Ltd

Mylan NV

National Institutes of Health

Nature's Plus Farmacêutica Ltda

NeoQuimica

Nortis Farmaceutica Ltda

Novartis AG

Novartis Biociências

Novo Nordisk A/S

Nycomed

OdontoPrev

Omint Serviços de Saúde

Oncoprod

Optimer Pharmaceuticals Inc

Organisation for Economic Co-operation and Development (OECD)

Orygen  Biotecnologia

Otsuka Pharmaceutical Co Ltd

Pan American Health Organization

Panpharma

Pasteur Institute

Pele Nova Biotecnologia SA

Pfizer Inc

PharmaPraxis

Porto Seguro - Seguro Saúde

Probiomed SA de CV

Probiotica Laboratórios Ltda

Procter and Gamble Co

Profarma

Profarma Specialty SA

Pró-Genéricos (the Brazilian Association of Generic Drug Industries)

Protalix BioTherapeutics Inc

Quesada Farmacêutica SA

Quintiles Inc

Raia Drogasil

Raia SA

Ranbaxy Laboratories Ltd

Reckitt Benckiser Group PLC

Roche Diagnostica Brasil

Rosário

Sabin Vaccine Institute

Sandoz Brazil

Sandoz do Brasil Indústria Farmacêutica

Sanofi

Sanofi Pasteur SA

Sant'Ana S.A. Drogaria Farmácias

Santa Cruz Distribuidora de Medicamentos

São Paulo Stock Exchange

Savicevic Participacoes SA

SC Participações Empresariais Ltda

Schwarz Pharma

Serum Therapeutic Institute

Shasun Pharmaceuticals Ltd

Sinclair IS Pharma PLC

Sindicato do Comércio Atacadista de Drogas, Medicamentos, Correlatos, Perfumarias, Cosmeticos e Artigos de Toucador no Estado de São Paulo (SINCAMESP)

Sindusfarma

Sistema Único de Saúde (SUS)

State Pharmaceutical Laboratory of Pernambuco (LAFEPE)

Strides Arcolab

Sun Pharmaceutical Industries Ltd

Supera Farma Laboratorios

Takeda Pharmaceutical Company Ltd

Telefônica Digital

Teva Pharmaceutical Industries Ltd

The Walgreen Company

The Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples (GTPI/Rebrip

TKS Farmacêutica Ltda

Torrent Pharmaceuticals Ltd

UCB Pharma SA

UERJ (Universidade do Estado do Rio de Janeiro)

União Química  Farmacêutica Nacional SA

UNICAMP (Universidade Estadual de Campinas)

Unimed Seguros Saúde

University of São Paulo

University of Texas

Valeant Pharmaceuticals International Inc

Walter Reed Army Institute of Research

Warc

Watson Pharmaceuticals Inc

Wockhardt Ltd

World Bank

World Health Organization (WHO)

Yasuda Marítima Saúde Seguros SA

Zydus Cadila

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd